BMS
Teva appoints new president and chief executive
May 10, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Jeremy Levin, Teva
Ex-BMS head Dr Jeremy Levin has been appointed president and chief executive of Teva. Prior to joining Teva, Levin, who …
GSK to bring pharma plant in Sri Lanka online
April 24, 2012Manufacturing and Production BMS, GSK. Sri-Lanka, manufacturing and production
GlaxoSmithKline is due to open a newly-built manufacturing facility in Sri Lanka this week that is said to be the …
Amylin dismisses BMS acquisition deal
March 30, 2012Manufacturing and Production, Sales and Marketing Amylin, BMS, Bydureon, diabetes, lilly
Amylin Pharmaceuticals has rebuffed a $3.5 billion unsolicited takeover bid from Bristol-Myers Squibb, according to reports. Shares in Amylin rose …
Sanofi sets up cholesterol drug showdown with Amgen
March 27, 2012Research and Development, Sales and Marketing Amgen, BMS, LDL, Lipitor, Merck, Regeneron, Sanofi
Sanofi and Amgen have posted results for their new injectable cholesterol drugs within 24 hours of each other. Both drugs …
Roche’s melanoma pill launched in UK
March 14, 2012Sales and Marketing BMS, CDF, NICE, Roche, Yervoy, Zelboraf
Roche’s Zelboraf has been launched in the UK to treat the deadliest form of skin cancer. Zelboraf (vemurafenib) is the …
Bristol-Myers Squibb elects Gerald Storch to board of directors
January 26, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing BMS, Gerald Storch
Bristol-Myers Squibb has announced that its board has elected Gerald Storch to serve as a member of the audit committee, …
AZ and BMS diabetes drug needs more data
January 20, 2012Research and Development, Sales and Marketing AstraZeneca, BMS, FDA approvals, diabetes
AstraZeneca and Bristol-Myers Squibb must supply more data on their diabetes treatment dapagliflozin, the FDA says.Currently being developed as monotherapy, …
Former Bristol-Myers Squibb man becomes head of Savient Europe
January 18, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Savient
Savient Pharmaceuticals has appointed David Veitch as the new president of its European division. Veitch joins the specialist biopharma firm …
AstraZeneca looks for new partners to bolster pipeline
January 16, 2012Business Services, Research and Development, Sales and Marketing AstraZeneca, BMS
AstraZeneca has used a recent healthcare conference in San Francisco to call for new drug development partners. Speaking at the …
NICE says yes to Tasigna for resistant disease
January 13, 2012Sales and Marketing BMS, Glivec, NICE, Novartis, Tasigna
NICE is recommending Novartis’ Tasigna for chronic myeloid leukaemia patients that can no longer use Glivec. In final guidance it …
BMS to buy hep C firm Inhibitex for $2.5 billion
January 9, 2012Research and Development, Sales and Marketing BMS, Inhibitex, hep C
Bristol-Myers Squibb will acquire virology specialist Inhibitex for $2.5 billion, expanding its infectious disease portfolio. Bristol-Myers Squibb will acquire the …
BMS in cholesterol alliance with China’s Simcere
December 16, 2011Sales and Marketing BMS, CETP inhibitor, Simcere, cardiovascular, emerging markets
Bristol-Myers Squibb is to co-develop a new compound to treat cardiovascular disease with Chinese firm Simcere Pharmaceutical Group. The companies, …
Stroke crisis to hit UK unless government acts, warns report
December 5, 2011Sales and Marketing BMS, Pfizer, Pradaxa, UK, stroke
Major improvements are needed in the treatment of atrial fibrillation to avoid a UK stroke epidemic, according to a new …
NICE okays Eliquis for blood clots after surgery
November 25, 2011Research and Development, Sales and Marketing BMS, Eliquis, NICE, Pfizer
NICE is recommending Pfizer and Bristol-Myers Squibb’s Eliquis for blood clots after surgery. Specifically, NICE has said that Eliquis (apixaban) …
Eliquis fails in head-to-head study against Lovenox
November 14, 2011Research and Development, Sales and Marketing BMS, Eliquis, Lovenox, Pfizer
Bristol-Myers Squibb and Pfizer have suffered a setback in their attempts to cement Eliquis’ place in the $20 billion market …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
